Record Revenue, Trailing Profits—Aarti's Margin Squeeze Isn't Temporary

Aarti Industries delivered record revenue at ₹3,668.4 crore in Q2 FY-2027, up 74.7% year-on-year. On the surface, the earnings looked strong: net profit at ₹168.7 crore, up 59.9% YoY. But the gap between those two growth rates—a 15 percentage point lag—is the defining story of the quarter. Profit growth did not keep pace with revenue growth, signaling margin compression. Management attributes this to raw material cost pass-through lags in acid, dyes, and pharma chains, where price inflation has not yet fully flowed through to customers. The company doubled inventory to hedge against further commodity swings, creating a material reversal risk if crude, sulfur, and aniline prices fall.

Of the incremental profit growth, approximately ₹50–60 crore of H1FY-2027 P&L gains came from inventory valuation adjustments, according to management disclosures. In Q2 alone, that translates to roughly ₹25–30 crore of non-recurring relief. Strip that out, and adjusted Q2 PAT drops to approximately ₹140–145 crore—still positive but materially lower than reported. This is a red flag for earnings quality. If raw material prices weaken, this gain will reverse, dragging H2 profit lower.

The revenue figure discrepancy (claimed ₹3,887 Cr vs. delivered ₹3,668.4 Cr) is worth noting. While a 5.6% gap could reflect accounting scope differences (e.g., co-packing revenue), management did not reconcile it on the call. This is a minor but telling detail—the gap was not addressed.

The structural story—Zone IV, the new specialty contract, Augene JV—is robust and multi-year. But the Energy segment surge (now 50% of portfolio) is a double-edged sword. While Fuel Additives capacity expanded to 360 KTPA and Calcium Chloride is benefiting from pricing uplift, the segment is entirely dependent on crude oil and refinery margins. Management sees this as cyclical, targeting 30–40% steady-state. If crude weakens materially, this entire profit buffer evaporates.

The honest read: Aarti is executing on structural catalysts (Zone IV, new contracts, Augene), but Q2 was a step forward on revenue and a step backward on margins. Margin recovery timing remains opaque. The market is right to remain cautious until inventory unwinds and profit leverage becomes evident.

The stock is trading at ₹441.2, well below its SMA20 (₹456), SMA50 (₹479), and SMA200 (₹463). RSI sits at 42.1 (neutral, not oversold). The 52-week range is ₹338–₹552, meaning the stock is mid-band—but the all-time high was ₹1,168, a 62% drawdown. While the stock has recovered 30.5% from its 52-week low, it remains below major moving averages despite strong earnings. The market is not re-rating higher on the Q2 print.

Ownership has shown subtle shifts. FII stake is at 6.99% (down 0.39pp QoQ), DII at 21.11% (up 0.99pp QoQ), and promoters at 41.82%. The FII trim is modest but noteworthy—global institutions are not adding on strength. Domestic institutions are accumulating, but FII hesitation suggests skepticism on execution and margin durability.

The market's verdict: cautious acknowledgment of structural catalysts, but skepticism on near-term margin recovery and inventory risk. The stock is fairly valued, not cheap. There is no bargain here.

Can Aarti execute Zone IV, new contracts, and Augene JV ramp while managing RM cost pass-through lag and inventory risk? That is the single question animating the stock. Bulls own the structural catalysts (multi-year ₹1,800 Cr FY28 EBITDA target, each component credible). Bears counter that near-term margin compression, inventory overhang, and execution risk will offset upside through H2 FY27. The honest read: Aarti is a solid execution franchise with real multi-year catalysts, but Q2 was a step forward on revenue and a step backward on margins. The market is right to remain cautious until inventory unwinds and margin recovery is evident.